• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Y-mAbs Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    9/16/25 8:59:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $YMAB alert in real time by email
    false --12-31 0001722964 0001722964 2025-09-16 2025-09-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549  

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): September 16, 2025

     

     

     

    Y-MABS THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-38650   47-4619612
    (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (IRS Employer Identification No.)

     

    202 Carnegie Center

    Suite 301

    Princeton, New Jersey, 08540

    (Address of principal executive offices) (Zip Code)

     

    (646) 885-8505

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

     

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class:   Trading symbol:   Name of each exchange on which registered:
    Common Stock, $0.0001 par value   YMAB   Nasdaq Global Select Market

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company  ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

     

     

    Item 2.01 Completion of Acquisition or Disposition of Assets.

     

    Agreement and Plan of Merger

     

    As previously disclosed in the Current Report on Form 8-K filed by Y-mAbs Therapeutics, Inc., a Delaware corporation (the “Company”), with the U.S. Securities and Exchange Commission (the “SEC”) on August 4, 2025, the Company is party to an Agreement and Plan of Merger, dated as of August 4, 2025 (the “Merger Agreement”), with Perseus BidCo US, Inc., a Delaware corporation (“Parent”), and Yosemite Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”) and; solely for purposes of Section 5.16 and Article 8 thereof, Stark International Lux, a Luxembourg private limited liability company (société à responsabilité limitée).

     

    Pursuant to the Merger Agreement, upon the terms and subject to the conditions thereof, on August 18, 2025, Purchaser commenced a cash tender offer (the “Offer”) to acquire all of the outstanding shares of common stock of the Company, par value $0.0001 per share (the “Shares”), at a price of $8.60 per Share (the “Offer Price”) in cash, without interest and subject to any applicable withholding of taxes and subject to the satisfaction or waiver, to the extent permitted under applicable legal requirements, of certain conditions set forth in the Merger Agreement.

     

    The Offer expired at one minute following 11:59 p.m., Eastern Time, on September 15, 2025 (such date and time, the “Expiration Time”) and was not extended. Equiniti Trust Company, LLC, in its capacity as depositary for the Offer (the “Depositary"), advised the Company that approximately 39,827,138 Shares were validly tendered (excluding any Shares tendered pursuant to guaranteed delivery procedures that have not yet been received by the Depositary for the Offer, as defined by Section 251(h)(6) of the General Corporation Law of the State of Delaware (the “DGCL")) and not validly withdrawn pursuant to the Offer, representing approximately 87.22% of the then outstanding Shares. Accordingly, the Minimum Condition (as defined in the Merger Agreement) has been satisfied. Purchaser has accepted for payment all Shares that were validly tendered and not validly withdrawn pursuant to the Offer prior to the Expiration Time and payment for such Shares has been or will be made promptly in accordance with the terms of the Offer.

     

    Following the completion of the Offer and the satisfaction or waiver of certain conditions set forth in the Merger Agreement, on September 16, 2025, Parent, Purchaser and the Company, pursuant to Section 251(h) of the DGCL and without a vote of the Company’s stockholders, effected a merger of Purchaser with and into the Company (the “Merger”), with the separate corporate existence of Purchaser ceasing and the Company surviving the Merger under the name “Y-mAbs Therapeutics, Inc.” as a wholly owned subsidiary of Parent, pursuant to the Merger Agreement (the “Surviving Corporation”).

     

    At the effective time of the Merger (the “Effective Time”), each Share then outstanding (other than Shares (a) held by the Company (or in the Company’s treasury), Parent, Purchaser, any other direct or indirect wholly owned subsidiary of Parent, or by stockholders of the Company who have properly exercised and perfected their statutory rights of appraisal under Delaware law, or (b) irrevocably accepted for purchase in the Offer (such Shares described in clause (a) and clause (b) of this paragraph, the “Excluded Shares”) was converted into the right to receive the Offer Price (the “Merger Consideration”), without interest and subject to any applicable withholding of taxes.

     

    In addition, at the Effective Time:

     

    ·each of the Company’s stock options (the “Options”) outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Each Option with an exercise price equal to or in excess of the Merger Consideration was automatically cancelled for no consideration;

     

    ·each of the Company’s restricted stock unit awards other than the PSU Awards (as defined below) (the “RSU Awards”) outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the total number of Shares issuable in settlement of such RSU Award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration; and

     

    ·each of the Company’s restricted stock unit awards that are subject to any performance-based vesting conditions (the “PSU Awards”) outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PSU Award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration.

     

     

     

     

    The aggregate consideration paid in the Offer and the Merger was approximately $413 million without giving effect to related transaction fees and expenses, which Parent funded through a combination of cash on hand and short-term financing.

     

    The foregoing description of the Merger Agreement is qualified in its entirety by reference to the Merger Agreement, which was filed as Exhibit 2.1 of the Current Report on Form 8-K filed by the Company with the SEC on August 5, 2025, and is incorporated by reference herein.

     

    The information set forth in Items 3.01, 5.01 and 5.03 is incorporated by reference into this Item 2.01.

     

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    In connection with the consummation of the Offer and the Merger, on September 16, 2025, the Company requested that the Nasdaq Global Select Market (“Nasdaq”) suspend the Shares from trading effective as of the open of trading on September 16, 2025, remove the Shares from listing on Nasdaq and file with the SEC an application on Form 25 to report the delisting of the Shares from Nasdaq (the “Form 25”). Nasdaq has informed the Company that on September 16, 2025, in accordance with the Company’s request, Nasdaq filed the Form 25 with the SEC in order to provide notification of such delisting and to effect the deregistration of the Shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company intends to file with the SEC a Form 15 with respect to the Shares, requesting the deregistration of the Shares under Section 12(g) of the Exchange Act and the suspension of the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act.

     

    Item 3.03 Material Modification to Rights of Security Holders.

     

    The information contained in Items 2.01 and 3.01 above and in Items 5.01 and 5.03 below of this Current Report on Form 8-K is incorporated herein by reference. From and after the Effective Time, holders of Shares (other than Excluded Shares) immediately prior to such time ceased to have any rights as stockholders of the Company (other than their right to receive the Merger Consideration for each Share held, pursuant to the Merger Agreement).

     

    Item 5.01 Changes in Control of Registrant.

     

    At the Effective Time, the Company became a wholly owned subsidiary of Parent. As a result of Purchaser’s acquisition of the Shares pursuant to the Offer and the consummation of the Merger, a change of control of the Company occurred. The information contained in Items 2.01, 3.01 and 3.03 above and in Items 5.02 and 5.03 below of this Current Report on Form 8-K is incorporated herein by reference.

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Resignation of Directors

     

    Effective immediately following and contingent upon the consummation of the Merger, Thomas Gad, David N. Gill, Laura J. Hamill, James I. Healy, Michael Rossi, Ashutosh Tyagi and Johan Wedell-Wedellsborg resigned from his or her position as a member of the Company’s board of directors (the “Board”) and all committees thereof. Such resignations from the Board were in connection with the transactions contemplated by the Merger Agreement and were not a result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices or any other matter.

     

    Resignation of Certain Officers

     

    In addition, effective immediately following and contingent upon the consummation of the Merger, Michael Rossi resigned as the Company’s President and Chief Executive Officer, Thomas Gad resigned as the Company’s Chief Business Officer, Peter Pfreundschuh resigned as the Company’s Executive Vice President, Chief Financial Officer and Treasurer, Joris Wiel Jan Wilms resigned as the Company’s Senior Vice President and Chief Operating Officer, Douglas J. Gentilcore resigned as the Company’s Senior Vice President and Danyelza Business Unit Head, John LaRocca resigned as the Company’s Senior Vice President and General Counsel and Secretary and Robert Gunning resigned as the Company’s Assistant Treasurer. Such resignations were in connection with the transactions contemplated by the Merger Agreement and were not a result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices or any other matter.

     

    Successor Directors and Officers

     

    At the Effective Time, in connection with the Merger and in accordance with the terms of the Merger Agreement, the directors of Purchaser, Vanessa Wolfeler, Robert Duffield and Daniel Dolan, became the directors of the Surviving Corporation.

     

    Also in connection with the Merger and in accordance with the terms of the Merger Agreement, the following individuals became the officers of the Surviving Corporation in the offices set forth opposite their names below:

     

    Vanessa Wolfeler – President

    Robert Duffield – Secretary

    Daniel Dolan – Treasurer

     

    Biographical information regarding Ms. Wolfeler and Messrs. Duffield and Dolan can be found in Schedule I of the Offer to Purchase, which was filed as Exhibit (a)(1)(i) to the Tender Offer Statement on Schedule TO filed by Parent and Purchaser with the SEC on August 18, 2025, as subsequently amended, which information is incorporated by reference into this Item 5.02.

     

     

     

     

    Item 5.03 Amendments to Articles of Incorporations or Bylaws, Change in Fiscal Year.

     

    Pursuant to the Merger Agreement, at the Effective Time, the certificate of incorporation of the Company (the “Certificate of Incorporation”) was amended and restated in its entirety. The Certificate of Incorporation is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference. In addition, pursuant to the Merger Agreement, at the Effective Time, the Company’s by-laws (the “By-Laws”) were amended and restated in their entirety. The By-Laws are filed as Exhibit 3.2 to this Current Report on Form 8-K and are incorporated herein by reference.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    2.1   Agreement and Plan of Merger, dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc., Perseus BidCo US, Inc., Yosemite Merger Sub, Inc., and solely for purposes of Section 5.16 and Article 8 thereof, Stark International Lux (filed as Exhibit 2.1 to Y-mAbs Therapeutics Inc.’s Current Report on Form 8-K, filed on August 5, 2025, and incorporated herein by reference)*
    3.1   Amended and Restated Certificate of Incorporation of Y-mAbs Therapeutics, Inc.
    3.2   Amended and Restated By-Laws of Y-mAbs Therapeutics, Inc.
    104   Cover Page Interactive Data File (embedded with the Inline XBRL document)

     

    * Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to provide copies of any of the omitted exhibits and schedules upon request by the SEC.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Y-MABS THERAPEUTICS, INC.
       
    Dated: September 16, 2025 By: /s/ Vanessa Wolfeler
        Vanessa Wolfeler
        President

     

     

     

    Get the next $YMAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $YMAB

    DatePrice TargetRatingAnalyst
    4/22/2025$3.00Neutral → Underperform
    BofA Securities
    11/18/2024$23.00Outperform
    Oppenheimer
    8/16/2024$20.00Overweight
    Cantor Fitzgerald
    6/28/2024$21.00Buy
    Truist
    5/10/2023$5.00 → $13.00Neutral → Outperform
    Wedbush
    4/3/2023Buy → Neutral
    Guggenheim
    1/27/2023$4.00Equal-Weight → Underweight
    Morgan Stanley
    1/5/2023Outperform → Market Perform
    Cowen
    More analyst ratings

    $YMAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hamill Laura returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

    9/19/25 6:00:15 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wg Biotech Aps closing all direct ownership in the company (SEC Form 4)

    4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

    9/18/25 9:39:55 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by SVP, Danyelza Bus. Unit Head Gentilcore Douglas J

    4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

    9/18/25 9:29:01 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

    Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire Y-mAbs in $412.0 million transaction; transaction expected to close by the fourth quarter of 2025, subject to completion of tender offer and other customary conditionsAs of June 30, 2025, cash and cash equivalents were $62.3 millionIn light of the pending transaction, Y-mAbs will not be holding a webcast and conference call to discuss its second quarter 2025 results PRINCETON, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commer

    8/8/25 6:35:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

    PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on Friday, August 8, 2025. In light of the previously announced transaction with affiliated entities of SERB Pharmaceuticals, Y-mAbs will not be hosting an earnings conference call. About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and

    8/7/25 7:30:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics

    Acquisition to Include Naxitamab-gqgk DANYELZA® (Naxitamab-gqgk), Further Broadening SERB's Rare Oncology Product Portfolio Transaction Expands SERB's Investment in the U.S. SERB to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Y-mAbs for $8.60 Per Share Represents 105% Premium to Y-mAbs Closing Share Price on August 4, 2025 WEST CONSHOHOCKEN, Pa. and PRINCETON, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals ("SERB"), a global specialty pharmaceutical company focused on medicines for rare diseases and medical emergencies, and Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) ("Y-mAbs" or "the Company"), a commercial-stage biopharmaceutical company focused on

    8/5/25 8:30:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Y-mAbs Therapeutics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Y-mAbs Therapeutics from Neutral to Underperform and set a new price target of $3.00

    4/22/25 7:23:34 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Y-mAbs Therapeutics with a new price target

    Oppenheimer initiated coverage of Y-mAbs Therapeutics with a rating of Outperform and set a new price target of $23.00

    11/18/24 8:23:54 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Y-mAbs Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Y-mAbs Therapeutics with a rating of Overweight and set a new price target of $20.00

    8/16/24 7:40:36 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    SEC Filings

    View All

    SEC Form 15-12G filed by Y-mAbs Therapeutics Inc.

    15-12G - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)

    9/26/25 8:30:07 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Y-mAbs Therapeutics Inc.

    EFFECT - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)

    9/17/25 12:15:04 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Y-mAbs Therapeutics Inc.

    S-8 POS - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)

    9/16/25 9:10:19 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $YMAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    FDA Approval for DANYELZA issued to Y-MABS THERAPEUTICS INC

    Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:

    3/21/24 10:20:07 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wg Biotech Aps bought $44,232 worth of shares (6,455 units at $6.85), increasing direct ownership by 0.14% to 4,559,233 units (SEC Form 4)

    4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

    12/12/23 8:27:16 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedell-Wedellsborg Johan bought $44,232 worth of shares (6,455 units at $6.85) (SEC Form 4)

    4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

    12/12/23 8:26:25 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wg Biotech Aps bought $40,190 worth of shares (6,183 units at $6.50) and bought $850,222 worth of shares (121,366 units at $7.01), increasing direct ownership by 3% to 4,552,778 units (SEC Form 4)

    4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

    12/11/23 5:25:50 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    Leadership Updates

    Live Leadership Updates

    View All

    Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

    NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. "I am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head," said Michael Rossi, President and Chief Executive Officer. "We believe Doug's extensive experience leading pharmaceutical commercialization and operations on a global scale will be instrumental in our co

    1/10/25 7:35:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

    NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. "Y-mAbs is at a critical inflection point as we continue to gain U.S. commercial traction with DANYELZA® while simultaneously advancing the development of our differentiated Self-Assembly DisAssembly Pre

    7/1/24 4:05:00 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

    NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer. "We are thrilled to welcome Dr. LaFrance to Y-mAbs," Mike Rossi, President and Chief Executive Officer. "Norman has an impressive track record in the research, development and commercialization of radiotherapeutics, molecular imaging, diagnostic and therapeutic products. With his deep expertise in develop

    6/5/24 7:05:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    Financials

    Live finance-specific insights

    View All

    Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

    Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire Y-mAbs in $412.0 million transaction; transaction expected to close by the fourth quarter of 2025, subject to completion of tender offer and other customary conditionsAs of June 30, 2025, cash and cash equivalents were $62.3 millionIn light of the pending transaction, Y-mAbs will not be holding a webcast and conference call to discuss its second quarter 2025 results PRINCETON, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commer

    8/8/25 6:35:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

    PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on Friday, August 8, 2025. In light of the previously announced transaction with affiliated entities of SERB Pharmaceuticals, Y-mAbs will not be hosting an earnings conference call. About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and

    8/7/25 7:30:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

    Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma updated to include naxitamab-gqgk (DANYELZA®)Dosed first patient in Phase 1 clinical trial evaluating CD38-SADA pretargeted radioimmunotherapy in patients with Relapsed/Refractory non-Hodgkin Lymphoma (Trial 1201)The Company to host virtual Radiopharmaceutical R&D update discussing Part A clinical data from its Phase I GD2-SADA clinical trial (Trial 1001) and announcing radioimmunotherapy and pipeline strategy on May 28, 2025As of March 31, 2025, cash and cash equiv

    5/13/25 6:35:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.

    SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

    11/14/24 4:32:10 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.

    SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

    11/12/24 6:00:40 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.

    SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

    11/4/24 2:16:23 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care